Comparison · NCT03298945-3f2d5bcb
Golytely vs Miralax-Gatorade Prep: Population Level Adenoma Detection Rate (ADR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Golytely vs Miralax-Gatorade Prep: Population Level Adenoma Detection Rate (ADR). Trial comparisons, record NCT03298945-3f2d5bcb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03298945-3f2d5bcb
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.336 | 0.309 | 0.364 | wilson | |
| Risk in group 2 | 0.331 | 0.304 | 0.359 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00535 | -0.0337 | 0.0443 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.904 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.859 | 1.22 | log | |
| Number needed to treat, for one more participant with the outcome on Golytely than on Miralax-Gatorade Prep | 187 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Golytely | 4-L split-dose Golytely bowel prep~Golytely: 4-L split dose Golytely is the current standard prep at the VA | 383 | 1,139 | OG000 |
| Group 2 | Miralax-Gatorade Prep | 2-L split-dose Miralax-Gatorade bowel prep~Miralax-Gatorade Prep: 2-L split-dose Miralax-Gatorade bowel prep for colonoscopy | 364 | 1,100 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Population Level Adenoma Detection Rate (ADR)
- Description
- the ADR is estimated as the proportion of patients with at least one adenoma detected among all patients scheduled for colonoscopy.
- Time frame
- within 1 month of colonoscopy
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens
- NCT number
- NCT03298945
- Phases
- PHASE4
- Conditions
- Colorectal Cancer
- Interventions
- Miralax-Gatorade Prep, Golytely
- Lead sponsor
- VA Office of Research and Development
- Results first posted
- 2025-01-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03298945?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03298945-3f2d5bcb